MK-677 (Ibutamoren) and Rosuvastatin Interaction: What You Need to Know

What Is the Core Interaction Between MK-677 and Rosuvastatin?

The central concern is that ibutamoren can alter hepatic drug transporter function and glucose-insulin signaling, two pathways that directly affect how rosuvastatin is absorbed, distributed, and cleared. Rosuvastatin is one of the statins most dependent on hepatic uptake transporters (OATP1B1 and OATP1B3) and on the efflux transporter BCRP for its pharmacokinetics. Any compound that inhibits these proteins can sharply increase rosuvastatin's systemic exposure, raising the probability of dose-dependent side effects including myopathy and rhabdomyolysis.

Why Rosuvastatin Is Particularly Vulnerable

Unlike atorvastatin or simvastatin, rosuvastatin is not primarily metabolized by CYP3A4. Its plasma exposure depends far more on hepatic uptake via OATP1B1 and OATP1B3, coded by SLCO1B1 and SLCO1B3, and on efflux via BCRP (ABCG2). The FDA's rosuvastatin prescribing information explicitly lists OATP inhibitors as a reason to cap rosuvastatin doses, stating: "Rosuvastatin Cmax and AUC were increased 2-fold when co-administered with a combination of lopinavir 400 mg and ritonavir 100 mg" due in part to OATP inhibition [1]. A similar, though likely smaller, magnitude of increase could occur with any agent that meaningfully inhibits these transporters.

The 2017 FDA Drug Interaction Guidance for Industry reinforces that OATP1B1/1B3 substrates like rosuvastatin require dedicated clinical or in vitro inhibition assessment before combining with novel compounds [2].

Where Ibutamoren Fits In

Ibutamoren (MK-677) is a non-peptide ghrelin receptor agonist. It stimulates pulsatile GH secretion from the pituitary, raising both GH and IGF-1 over 24 hours without suppressing the hypothalamic-pituitary axis the way exogenous GH injections do. A 2006 randomized controlled trial (N=65, 2-year duration) published in the Annals of Internal Medicine showed that MK-677 60 mg/day raised IGF-1 by 40% above baseline in older adults [3]. That sustained IGF-1 elevation is relevant: IGF-1 and GH signal through pathways that can modify hepatic gene expression, including genes governing transporter proteins.

Preclinical data suggest GH/IGF-1 signaling modulates OATP expression in the liver, though dedicated human pharmacokinetic studies pairing ibutamoren with rosuvastatin have not been published as of this writing.

Pharmacokinetic Mechanism in Detail

OATP1B1 and OATP1B3 Transporter Competition

OATP1B1 and OATP1B3 are sinusoidal uptake transporters located on the basolateral membrane of hepatocytes. They pull rosuvastatin from portal blood into liver cells, which is where the drug exerts its cholesterol-lowering effect. If ibutamoren or its downstream hormonal effects reduce OATP activity, rosuvastatin stays in systemic circulation longer and at higher concentrations.

The clinical consequence of OATP inhibition is well-documented in the statin literature. A genome-wide association study published in NEJM (N=85 myopathy cases vs. 90 controls) found that the SLCO1B1 c.521T>C variant, which reduces OATP1B1 function, increased simvastatin-related myopathy risk by an odds ratio of 16.9 per copy of the C allele [4]. While that data is specific to simvastatin, the principle applies to rosuvastatin because it uses the same transporter pathway.

BCRP Efflux Pathway

BCRP (breast cancer resistance protein) is an ABC efflux transporter expressed at the hepatocyte canalicular membrane and in the gut epithelium. It limits rosuvastatin oral bioavailability and facilitates biliary excretion. The FDA label for rosuvastatin notes that BCRP inhibitors such as atazanavir can raise rosuvastatin AUC by approximately 213% [1]. Ibutamoren's direct effect on BCRP is not established in human data, but GH-IGF-1 signaling has been shown in rodent hepatocyte models to alter ABC transporter expression [5].

CYP Enzyme Involvement

Rosuvastatin undergoes minimal CYP2C9 metabolism (roughly 10% of clearance). Ibutamoren does not appear to be a strong CYP inhibitor based on available in vitro data. This pathway is therefore a lower-priority concern compared to transporter interactions. Patients on CYP2C9 inhibitors such as fluconazole or amiodarone alongside both drugs would face compounded risk.

Pharmacodynamic Interactions: Muscle and Metabolic Effects

Myopathy Risk

Both agents affect skeletal muscle, though through different mechanisms. Statins reduce coenzyme Q10 (ubiquinol) biosynthesis by blocking the mevalonate pathway upstream of its synthesis, which impairs mitochondrial respiratory chain function in muscle fibers. Symptomatic statin myopathy affects approximately 5 to 10% of statin users in observational studies, though the rate in RCTs is closer to 1.5 to 3% [6].

Ibutamoren raises GH and IGF-1, which generally support muscle protein synthesis. That anabolic effect might appear protective, but the picture is more nuanced. Supraphysiologic GH exposure can cause fluid retention in muscle compartments and alter insulin sensitivity in muscle, which may mask early myalgia or confuse clinical evaluation. A patient on MK-677 who notices muscle soreness might attribute it to the anabolic effect of GH rather than to rosuvastatin-induced myopathy.

Glucose and Insulin Resistance

This is the most clearly documented pharmacodynamic interaction between the two drugs. Ibutamoren reliably raises fasting blood glucose. In the 2-year Annals trial, fasting glucose rose by a mean of 0.3 mmol/L (5.4 mg/dL) in the MK-677 group, and insulin resistance worsened as measured by homeostatic model assessment [3]. Rosuvastatin carries an FDA label warning for new-onset diabetes, with the JUPITER trial (N=17,802) reporting a 27% relative increase in physician-reported diabetes in the rosuvastatin 20 mg group versus placebo over a median 1.9 years [7].

Combining an agent that raises insulin resistance (ibutamoren) with one that has a diabetogenic class effect (rosuvastatin) could meaningfully increase the probability of dysglycemia in predisposed patients, particularly those with pre-diabetes, metabolic syndrome, or BMI >30 kg/m².

Fluid Retention and Blood Pressure

Ibutamoren causes dose-dependent sodium retention mediated by GH's action on renal tubules. This can raise blood pressure modestly. Elevated blood pressure is itself a cardiovascular risk factor that partially offsets the cardiovascular protection offered by rosuvastatin. Clinicians co-prescribing these agents should monitor blood pressure at each visit.

Severity Classification and Clinical Risk Stratification

Drug interaction databases (Lexicomp, Micromedex, Drugs.com) do not currently list a discrete MK-677 / rosuvastatin entry because ibutamoren is not FDA-approved and lacks an official drug monograph. That absence of a listed interaction does not mean the combination is safe. It means the interaction has not been formally adjudicated.

Based on available mechanistic data, the interaction severity can be reasonably classified as moderate to potentially major, depending on patient-specific factors.

Lower risk patients include those who are normoglycemic, have no personal or family history of statin myopathy, carry no SLCO1B1 or ABCG2 loss-of-function variants, and take rosuvastatin at doses of 5 to 10 mg/day.

Higher risk patients include those with pre-diabetes or diabetes, prior statin-related muscle symptoms, renal impairment (which slows rosuvastatin clearance), Asian ancestry (FDA labeling notes that Asian patients have approximately 2-fold higher rosuvastatin AUC compared to Caucasian patients, likely due to SLCO1B1 variant frequency) [1], or who take rosuvastatin at 20 to 40 mg/day.

Monitoring Protocol

Baseline Testing Before Starting the Combination

Clinicians should obtain the following before a patient begins ibutamoren while already on rosuvastatin, or vice versa:

• Fasting glucose and HbA1c (pharmacodynamic interaction baseline)
• Creatine kinase (CK) with a note that ibutamoren's anabolic effect may mildly raise CK at baseline
• Comprehensive metabolic panel including liver function tests
• Fasting lipid panel (to assess whether rosuvastatin dose is appropriate)
• Blood pressure measurement

Ongoing Monitoring Intervals

At 4 to 6 weeks after combining: recheck fasting glucose and CK. If CK exceeds 5 times the upper limit of normal without a clear alternative explanation such as intense exercise, rosuvastatin should be held and the clinical picture reassessed. The American College of Cardiology / AHA 2022 cholesterol guidelines recommend this threshold for statin discontinuation [8].

At 3 months: repeat HbA1c, lipid panel, and liver enzymes. Adjust rosuvastatin dose downward if LDL is below target by a wide margin, which could suggest elevated plasma rosuvastatin exposure.

Symptom-Based Monitoring

Patients should be instructed to report any of the following promptly: muscle pain, weakness, or brown/tea-colored urine (possible myoglobinuria); excessive thirst or urination (hyperglycemia); new or worsening edema; and unexplained fatigue. Brown urine with concurrent myalgia warrants same-day evaluation and a CK level.

Dose Considerations and Prescribing Guidance

Rosuvastatin Dose Ceiling

When hepatic transporter inhibition is suspected, the FDA recommends capping rosuvastatin at lower doses. For strong OATP inhibitors, the label restricts rosuvastatin to 10 mg/day [1]. Because ibutamoren's transporter effect is uncertain but plausible, a conservative ceiling of 5 to 10 mg/day of rosuvastatin is a reasonable starting point for patients who wish to use both agents.

If a patient requires higher-intensity statin therapy for established cardiovascular disease, switching to a statin with less OATP/BCRP dependence, such as fluvastatin (primarily CYP2C9) or pravastatin (renal clearance), may reduce interaction risk while preserving cardiovascular protection.

Ibutamoren Dose and Timing

Standard MK-677 research doses range from 10 mg/day to 25 mg/day in most published human studies. The 25 mg dose used in the 2-year Annals trial produced IGF-1 increases of approximately 40% and was the dose associated with worsened insulin resistance [3]. Patients using doses above 25 mg/day (which occurs frequently in the gray-market supplement context) face proportionally greater GH/IGF-1 elevation and thus greater potential for transporter modulation and glucose effects.

Taking ibutamoren in the evening, which many users do to align GH pulses with sleep, does not meaningfully separate the pharmacodynamic effects from a once-daily rosuvastatin dose because both glucose elevation and OATP modulation are sustained effects rather than acute peak effects.

When to Avoid the Combination Entirely

A prescriber should consider advising against combined use in patients who have:

• A prior episode of rhabdomyolysis on any statin
• CK elevation >3 times the upper limit of normal at baseline without explanation
• HbA1c of 6.5% or higher (frank diabetes) with poorly controlled glucose
• Severe renal impairment (eGFR <30 mL/min/1.73 m²), because rosuvastatin clearance falls and AUC rises independent of transporter effects [1]
• Concurrent use of other OATP inhibitors such as cyclosporine, gemfibrozil, or protease inhibitors

Patient Counseling Points

Patients often encounter MK-677 through bodybuilding forums or gray-market peptide vendors rather than through a licensed prescriber. That context creates a counseling challenge: many patients are not disclosing ibutamoren use to the physician who manages their rosuvastatin. Transparent disclosure is the single most important safety step.

Key messages for patients:

Tell your prescriber about every compound you take, including research chemicals, peptides, and over-the-counter supplements. Rosuvastatin interactions are dose-sensitive, and your prescriber cannot make an accurate risk assessment without complete information.

Muscle pain is not normal. A common assumption in the fitness community is that muscle soreness is expected on GH-promoting compounds. Persistent, non-exercise-related muscle pain while on rosuvastatin requires a CK test, not reassurance.

Glucose monitoring matters. If you have a glucometer, check fasting glucose weekly for the first month after starting the combination. A reading consistently above 126 mg/dL warrants a call to your prescriber.

Do not self-adjust rosuvastatin dose. Reducing your statin without medical supervision to "protect your liver" is a common practice in peptide-using communities, but unsupervised dose reduction increases cardiovascular risk in patients who genuinely need statin therapy.

What the Absence of Published RCT Data Actually Means

No dedicated pharmacokinetic trial has examined the ibutamoren-rosuvastatin pair as of early 2025. That data gap is not reassuring, because it means the magnitude of the interaction is unknown rather than proven to be negligible. In drug development, interactions between OATP substrates and novel compounds have repeatedly surprised investigators: the magnitude of the interaction between cyclosporine and rosuvastatin (a 10-fold AUC increase) was not predicted from early in vitro data [1].

Extrapolating from the pharmacology of GH/IGF-1 on hepatic transporters, the interaction is likely smaller in magnitude than cyclosporine. A 50 to 100% increase in rosuvastatin AUC with ibutamoren 25 mg/day would not be mechanistically implausible, though this is speculative and awaits formal study. A 100% increase in AUC on rosuvastatin 20 mg/day would be clinically equivalent to taking 40 mg/day, a dose at which myopathy rates in trials such as the CTT meta-analysis (N=174,000 patient-years) are meaningfully higher than at 10 mg/day [9].

The Cholesterol Treatment Trialists' Collaboration 2010 meta-analysis found that high-intensity statin therapy increased myopathy rate approximately 4-fold compared to low-intensity therapy [9]. Transporter-mediated AUC doubling could therefore push a patient from a low-risk to a moderate-risk myopathy category without any change in the labeled dose.